Sign in
Taking people in Hong KongNo phase

Radiation to Limited Cancer Spread in Liver Cancer Patients on Immunotherapy

Tests targeted radiation on a few growing liver tumors in adults with advanced liver cancer.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
SBRT in HCC With Oligoprogression on First-line Immunotherapy
Status
Recruiting
People taking part
27 people, planned
Started
21 Jun 2024
Expected to end
1 Mar 2028
Type of study
Interventional
Treatments tested
  • Stereotactic Body Radiation Therapy (SBRT)
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced liver cancer (HCC) whose cancer grew in only a few places while on first-line immunotherapy. They would get radiotherapy (SBRT) to the growing spots.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Confirmed HCC with limited progression (5 lesions or fewer in total) on first-line immunotherapy. Liver function must be Child-Pugh A. The growing lesions must be treatable with SBRT, within the size and number limits in the record.
Earlier treatment
Must have had first-line immunotherapy: atezolizumab plus bevacizumab, durvalumab plus tremelimumab, durvalumab, or nivolumab and ipilimumab. Earlier radiofrequency ablation (RFA) or TACE is allowed. No earlier radiotherapy to the abdomen and no earlier yttrium-90 chemoembolization.

Main reasons for not taking part

  • Another cancer in the last 5 years (except treated skin BCC or cervical CIN)
  • Pregnant or breastfeeding
  • Active autoimmune disease needing systemic therapy in the past 2 years
  • Immunodeficiency, including HIV
  • Ongoing corticosteroid therapy above 10mg prednisone daily

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients aged ≥ 18 years old
  • ECOG performance 0 to 1
  • Confirmed diagnosis of HCC
  • Oligoprogression on first-line immunotherapy, as defined as ≤ 5 lesions (intra- and extrahepatic lesions all together; vascular tumor thrombus is counted as one lesion); First-line immunotherapy that are allowed in this study include atezolizumab plus bevacizumab, durvalumab plus tremelimumab, durvalumab, nivolumab and ipilimumab, which are approved by the FDA and have been used in Hong Kong
  • Progressed lesion(s) amenable to SBRT:; For intrahepatic progression:; Number of intrahepatic progression ≤ 5; Total intrahepatic tumours ≤ 10; Maximum sum of HCC ≤ 20cm; Any one HCC ≤ 20cm; Normal liver volume minus intrahepatic GTV > 700cc; Mean liver dose ≤ 15Gy; No measurable common or main branch biliary duct involvement; No direct tumor invasion into the stomach, duodenum, small bowel or large bowel; For extrahepatic progression:; Maximal tumor size ≤ 7cm; Respective dose constraints of organ at risks as listed on the UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy can be met and ASTRO guideline
  • Prior radiofrequency ablation (RFA) or trans-arterial chemoembolization (TACE) are eligible
  • Child-Pugh A liver function
  • Life expectancy longer than 12 weeks
  • At least one measurable treatment lesion according to RECIST 1.1
  • Written informed consent must be obtained prior to any study related procedures
  • Adequate haematological function (Hb ≥ 8.5g/dL; Plt ≥ 50x10\^9/L; ANC ≥ 1.0x10\^9/L; INR ≤ 1.5)
  • Adequate hepatic function (albumin ≥ 28g/L; Bilirubin ≤ 2.5xULN; ALT < 5 times upper limit normal)
  • Adequate renal function (serum creatinine ≤ 1.5 times the upper limit of normal range; Na ≥ 130mmol/L; K ≥ 3.0mmol/L)
  • Able to read, understand and provide written consent

Who cannot take part

  • Previous radiotherapy to the abdomen
  • Previous yttrium-90 chemoembolization
  • Ongoing corticosteroid therapy >10mg prednisone daily
  • History of another malignancy except appropriately-treated BCC of skin or CIN of cervix during the last 5 years
  • Repetitive history of non-healing wounds or ulcers within 2 months of inclusion
  • Active autoimmune disease requiring systemic therapy in the past 2 years
  • Diagnosis of immunodeficiency (including HIV)
  • Pregnant or lactating females at any time during the study

Where in Hong Kong

  • Department of Clinical Oncology, Prince of Wales HospitalHong Kong, Hong KongContact: Landon L CHAN, MBChB, MScTaking people

About the trial

What the trial wants to find out

HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong. Patients with advanced HCC are treated with immunotherapy-based as first-line treatment as a standard of care. At the moment, there is limited evidence to guide subsequent treatments after patients progressed on immunotherapy. Oligoprogression is a term used to describe patients who had limited progression (usually less than 3 sites) on systemic therapy, with the rest of the lesions controlled. Previous studies in non-HCCs have shown that addition of locoregional treatment (e.g. radiotherapy) may prolong the use of systemic therapy, resulting in improved survival, but this has been relatively unexplored for HCC. In this prospective, single-arm study, we aim to evaluate the treatment outcome, efficacy and safety of the addition of radiotherapy to oligoprogressive sites for patients who had limited progression on First-line Immunotherapy.

The group in the trial

  • RadiotherapyTreatment being tested

    Suitable patients are consented and enrolled with the following treatment being given. * Continue of immunotherapy till next progression, intolerability, or death as per standard practice. * Radiotherapy will start 4 to 6 weeks after consent * For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks is generally recommended. * For extrahepatic progression: delivery of ablative dose (i.e. BED10≥100Gy) will be attempted. * Lower doses to be delivered (for both intrahepatic and extrahepatic lesions) based on nearby OAR dose constraints are allowed. The final dose and fractionation are at the discretion of the treating oncologist. * Bevacizumab will need to be withhold 4 weeks prior and after radiotherapy. PD-1 or PD-L1 therapy are allowed to be continued as per the latest ESTRO-ESMO consensus guideline. * Dose constraints to organ at risk (OAR) will take reference from RTOG-1112 and UK 2022 consensus on normal tissue dose-volume constraints and ASTRO 2022 guideline.

    Treatment: Stereotactic Body Radiation Therapy (SBRT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma With Oligoprogression on First-line Immunotherapy
Plain-language title
Radiation to Limited Cancer Spread in Liver Cancer Patients on ImmunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026